Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | SUCNR1 | Q9BXA5 | 13/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | FAAH | O00519 | 2/20 | 0.39 |
| ▸ | CES1 | P23141 | 1/20 | 0.39 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.39 |
| ▸ | OXGR1 | Q96P68 | 2/20 | 0.38 |
| ▸ | BDKRB1 | P46663 | 1/20 | 0.37 |
| ▸ | PPARA | Q07869 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6421236 | 1.00 | MAPT (0.46) | MAPTSUCNR1ALDH1A1FAAHCES1 | |
| SCHEMBL22223260 | 0.81 | SUCNR1 (0.42) | SUCNR1FAAHCES1DAGLAOXGR1 | |
| SCHEMBL17921405 | 0.80 | SUCNR1 (0.48) | SUCNR1ALDH1A1OXGR1BDKRB1 | |
| SCHEMBL24194292 | 0.79 | SUCNR1 (0.49) | SUCNR1ALDH1A1OXGR1BDKRB1 | |
| SCHEMBL6265814 | 0.77 | SUCNR1 (0.53) | SUCNR1ALDH1A1OXGR1BDKRB1 | |
| SCHEMBL30487489 | 0.75 | TDP1 (0.48) | SUCNR1ALDH1A1OXGR1BDKRB1 | |
| SCHEMBL21314499 | 0.75 | TDP1 (0.48) | SUCNR1ALDH1A1OXGR1BDKRB1 | |
| SCHEMBL22223345 | 0.75 | SUCNR1 (0.46) | SUCNR1ALDH1A1DAGLAOXGR1 | |
| SCHEMBL22223268 | 0.75 | ALDH1A1 (0.49) | SUCNR1ALDH1A1OXGR1 | |
| SCHEMBL20153683 | 0.75 | ALDH1A1 (0.50) | MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1040098-B1 | INTEGRIN RECEPTOR ANTAGONISTS | MERCK & CO INC (US) | 2005-04-27 | — | — | EP | disclosed |
| US-6784190-B2 | USEFUL FOR INHIBITING BONE RESORPTION, TREATING AND PREVENTING OSTEOPOROSIS, VASCULAR RESTENOSIS, DIABETIC RETINOPATHY, MACULAR DEGENERATION, ANGIOGENESIS, TUMOR, ATHEROSCLEROSIS, INFLAMMATION, WOUND HEALING, VIRAL DISEASEDISEASE, TUMOR | MERCK & CO., INC. | 2004-08-31 | — | — | US | disclosed |
| US-20020010176-A1 | Integrin receptor antagonists | MERCK SHARP & DOHME CORP. | 2002-01-24 | — | — | US | disclosed |
| US-6297249-B1 | SUBSTITUTED 2-CARBOXYALKYLPYRIDINES | MERCK & CO., INC. | 2001-10-02 | — | — | US | disclosed |
| US-6048861-A | OSTEOPOROSIS; BONE DISORDERS; CARDIOVASCULAR DISORDERS; ANTIINFLAMMATROY AGENTS; WOUND HEALING AGENTS | MERCK & CO., INC. (US) | 2000-04-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020010176-A1 | Integrin receptor antagonists | ITGAV, ITGB3, ADGRE5 | MAPT 4224/4885SUCNR1 579/4885ALDH1A1 2646/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.